Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.14%
#2 PulseChain PulseChain +54.75%
#3 Ontology Gas Ontology Gas +34.63%
#4 Merlin's Seal BTC Merlin's Seal BTC +33.38%
#5 BOOK OF MEME BOOK OF MEME +29.72%
#6 ConstitutionDAO ConstitutionDAO +25.40%
#7 Collect on Fanable Collect on Fanable +24.53%
#8 Unit Pump Unit Pump +24.29%
#9 Pump.fun Pump.fun +24.29%
#10 Neiro Neiro +23.35%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Molecure S.A. Molecure S.A.

Molecure S.A.

MOC
Rank in Stocks #26168
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in... Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
Share Price
$1.73
Market Cap
$42.88M
Change (1 day)
2.16%
Change (1 year)
-18.85%
Country
PL
Trade Molecure S.A. (MOC)

Category

Healthcare
P/E ratio for Molecure S.A. (MOC)
P/E ratio as of 2026 TTM: 0
According to Molecure S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Molecure S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.